← All trials
NCT04162002
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2019
- Primary completion
- Nov 18, 2019
- Completion date
- Nov 18, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- DeNova ResearchLead sponsor
- University of Illinois at ChicagoReponsible party - principal investigator
- GaldermaCollaborator
- DeNova ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.